Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bedromed
- Development stage
- Unknown
- Lead developer
- Bedrocan
- Modality
- Small Molecules
- Administration
- Sublingual, Buccal
01
Overview
Bedromed is a pharmaceutical-grade cannabinoid formulation developed by Bedrocan Deutschland, available as oromucosal drops and a sublingual oil-in-water emulsion spray. The product contains standardized concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) extracted from Cannabis sativa. Bedromed is indicated for the management of symptoms in conditions such as chronic pain, spasticity associated with multiple sclerosis, and chemotherapy-induced nausea and vomiting, particularly when conventional treatments are inadequate. By utilizing oromucosal and sublingual delivery, Bedromed aims to provide more consistent absorption and faster onset of action compared to traditional oral cannabinoid administration.
- Brand names
- Bedromed
- Other names
- Bedromed TropfenBedromed SprayBedromed dropsoromucosal cannabinoid formulation
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Bedromed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bedromed.